To study the effect of homoeopathy in cancer patients along with chemotherapy and radiotherapy

A pilot study evaluating role of Homoeopathic medicine in Lung Cancer patients as an adjuvant treatment to chemotherapy/radiotherapy,and correlating with Molecular Profiling - None

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/10/037391

Enrollment

Registered

2021-10-20

Start date

Unknown

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C34- Malignant neoplasm of bronchus andlung

Interventions

Intervention1: Standard management of Chemotherapy and Radiotherapy and Placebo: Early operable lung cancer(NSCLC Stage I and Stage II)surgical resection followed by adjuvant chemotherapy or chemoradi

Eligibility

Inclusion criteria

Inclusion criteria: Normal hemogram, normal LFT & KFT, Blood urea 10-50mg/dl, Creatinine Patient diagnosed with NSCLC Stage: I, II, III, and IVA

Exclusion criteria

Exclusion criteria: Uncontrolled Diabetes, Pregnant and lactating patients, Patient refusing to give written consent, Deranged LFT & KFT, Confirmed cases of HIV

Design outcomes

Primary

Measure	Time frame
To assess the improvement in QOL assess through FACT-G score To assess the loco-regional recurrence rate CTCAE grading of toxicity profileTimepoint: 2 years	—

Secondary

Measure	Time frame
To corelate with genomic and molecular signaling pathwaysTimepoint: 2 years	—

Countries

India

Contacts

Public ContactDr Rambha Pandey

AIIMS, Delhi

rambha151@gmail.com9310012026

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026